Surgery Partners Director Teresa DeLuca Buys 11,250 Shares

Teresa DeLuca, a Director at Surgery Partners (NASDAQ:SGRY), executed a direct purchase of 11,250 shares of common stock on Aug. 18, 2026, according to a SEC Form 4 filing.

Company snapshot

• Surgery Partners operates a nationwide network of surgical facilities and associated medical services across the United States.
• Its business consists of two segments, Surgical Facility Services and Ancillary Services, which provide non-urgent procedures across specialties, including orthopedics and gastroenterology.

Surgery Partners reported trailing-twelve-month revenue of $3.4 billion and a net loss of $88.6 million. As of the Aug. 19, 2026, market close, the company had a market capitalization of $1.8 billion.

Transaction summary

Transaction value based on SEC Form 4 weighted average purchase price ($14.33); post-transaction value based on Aug. 18, 2026, market close ($14.24).

Key questions

• What were the specific circumstances regarding the reporting of this trade?
  The disclosure was made through an amended SEC filing to correct the transaction size and execution price from a report previously submitted on Aug. 19, 2026.
• How significant is this acquisition relative to the insider's existing stake?
  This purchase increased DeLuca's direct equity stake by 20%, while the company's total insider ownership remains at 0.05%.
• What is the current valuation context for this purchase?
  The shares were acquired at $14.33 per share, compared with a market price of $13.60 as of the Aug. 19, 2026, market close.
• Does the insider maintain any indirect holdings or stock options?
  The current filing indicates that the director's entire beneficial ownership of 68,093 shares is held directly, with no reported indirect interests or derivative securities.

Company Overview

Company Snapshot

• Surgery Partners operates a nationwide network of surgical facilities and ancillary medical services, including ambulatory surgery centers and dedicated surgical hospitals that deliver non-urgent surgical procedures across specialties such as gastroenterology, general surgery, ophthalmology, orthopedics, and pain management.
• The company generates revenue through two primary segments: Surgical Facility Services, which operates the surgical venues and related infrastructure, and Ancillary Services, which provide complementary medical services that enhance the core surgical operations.
• The company serves healthcare providers, patients requiring elective surgical procedures, and health systems seeking to outsource surgical facility management, positioning itself as a critical infrastructure provider within the non-urgent surgical care market.

Surgery Partners operates as a scaled platform with 16,000 employees and $3.4 billion in TTM revenue, establishing itself as a significant player in the ambulatory and surgical hospital sector. The company's business model leverages a distributed network of surgical facilities to capture market share in non-urgent procedures while generating ancillary service revenue. Despite current profitability headwinds, the company's scale and diversified specialty focus provide a foundation for operational leverage and opportunities for market consolidation within the fragmented surgical services industry.

What this transaction means for investors

The Surgery Partners stock price has slumped 37.6% over the past 12 months as of this writing; in comparison, the S&P 500 is up 20%. One issue that may be affecting investor enthusiasm is the company's $4 billion in debt, compared with total cash of $216.7 million. Also, while the company generates significant revenue, the reported net income attributable to common shareholders over the trailing 12 months is a negative $88.6 million. With that context in mind, DeLuca's purchase may be welcome news for shareholders, as it signals confidence in the company's future. DeLuca significantly increased her holdings by purchasing 11,250, bringing her total holdings to just over 68,000.

Still, even with the stock price slumping over the last year, analysts also remain bullish on the upside for Surgery Partners. According to CNN, of the 12 analyts who cover the stock, 75% rate it as a buy, while 25% rate it as a hold. From that group of analysts, the median one-year price target is $19, representing a 35.9% gain from today's price. The highest price target in the group is $24, representing a 71.6% gain, while the lowest is $14, suggesting the stock is expected to trade flat over the next year.

Jack Delaney has no position in any of the stocks mentioned. The Motley Fool has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy.